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ABSTRACT
Background: Transcatheter occlusion of ostium secundum atrial 
septal defects using commercial available devices is a safe and 
effective procedure. We present our experience with two new 
generation coated nitinol wire devices. Methods: We report 
device characteristics, implantation technique and outcomes 
of patients with atrial septal defects treated with the Lifetech 
CERA™ ASD Occluder and the Cocoon Septal Occluder. Results: 
Procedures were performed in 49 patients, 37 were female. 
Ages ranged from 7 to 68 years and body weight from 17 to 
90 kg. The aortic rim was present in 34.7% and atrial septal 
aneurysms in 14.3% of the patients. Mean diameter was 13 
± 7 mm whereas the balloon stretched diameter was 22 ± 7 
mm. Implantation was possible in all cases and 55 devices 
were used. Forty-five CERA™ and four Cocoon devices were 
used. Three patients required occlusion of a second orifice. 
During the procedures the first device had to be replaced 
by a larger one in two cases, and in the third case it was 
replaced due to a tuliplike malformation of the left atrial disc. 
Immediate occlusion occurred in 91.9% and in 95.9% at 6 
months. There were no deaths or other significant complica-
tions. Conclusions: The use of both CERA™ and Cocoon 
devices was simple and reproducible in experienced hands. 
Short-term occlusion rates were similar to the ones obtained 
with the Amplatzer™ device. More studies and long-term 
follow-up are required to determine the actual advantages of 
coated nitinol wire devices.
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RESUMO
Oclusão Percutânea das Comunicações Interatriais 
Tipo Ostium Secundum com Próteses de  
Nitinol Revestidas de Última Geração
Introdução: A oclusão percutânea das comunicações inter-
atriais tipo ostium secundum com as próteses disponíveis 
comercialmente é procedimento seguro e eficaz. Apresentamos 
a experiência com duas próteses de nova geração, com fios 
de nitinol revestidos. Métodos: Descrevemos as características 
das próteses, a técnica de implante e os resultados de paci-
entes portadores de comunicações interatriais, tratados com 
as próteses Lifetech CERA® ASD Occluder e Cocoon Septal 
Occluder. Resultados: Foram realizados procedimentos em 49 
pacientes, sendo 37 do sexo feminino. A idade variou de 7 
a 68 anos, e o peso de 17 a 90 kg. Estavam presentes borda 
aórtica em 34,7% e aneurisma de septo atrial em 14,3% dos 
pacientes. Os diâmetros estáticos dos orifícios principais foram 
de 13 ± 7 mm e os diâmetros estirados de 22 ± 7 mm. O 
implante foi possível em todos os casos, sendo empregados 55 
dispositivos. Foram utilizadas próteses CERA® em 45 pacientes 
e Cocoon nos demais. Três pacientes necessitaram ocluir um 
segundo orifício. Durante os procedimentos, foi necessária a 
substituição da primeira prótese por outra de maior diâmetro 
em dois casos e por deformidade da prótese (configuração 
em tulipa) no terceiro caso. A oclusão imediata ocorreu em 
91,9% e em 95,9% no 6o mês. Não ocorreram óbitos ou 
outras complicações significativas. Conclusões: O manuseio 
das próteses CERA® e Cocoon foi simples e reprodutível nas 
mãos de operadores experientes. As taxas de oclusão imediata 
foram semelhantes às obtidas com as próteses Amplatzer®. Mais 
estudos e seguimento de longo prazo se fazem necessários 
para determinar as reais vantagens do revestimento dos fios 
de nitinol.
DESCRITORES: Comunicação interatrial. Cateterismo cardíaco. 
Próteses e implantes.
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T he percutaneous closure of ostium secundum-type interatrial communications (osASD), initially de-scribed by King and Mills in 1976,1 is, at present, 
the therapeutic method of choice universally accepted 
at all major centers. This procedure has proven safe 
and effective, making it an excellent alternative to 
conventional surgical treatment.
Despite excellent results in the short and medium 
term obtained with the Amplatzer Septal Occluder® 
prosthesis (ASO; AGA Medical Corp., Golden Valley, 
Minnesota, United States), new devices have been de-
veloped, aiming to correct deficiencies or suggesting 
modifications in the design of the prostheses, the amount 
and thickness of nitinol wires, the outer coating type 
to prevent the release of nickel into the bloodstream, 
and in different delivery mechanisms. Unfortunately, 
the number of publications in the literature on these 
new devices is scarce, perhaps because they are not 
available in the United States.2-4
For each of these new devices, there are advantages 
and disadvantages with respect to the technical aspects 
and to the profile of the prostheses. Prostheses registered 
by the Brazilian National Health Surveillance Agency 
(Agência Nacional de Vigilância Sanitária – ANVISA) 
and available in Brazil offer a choice of an interesting 
treatment with safety, efficacy, and reproducibility, so 
that the professional can choose the device that best 
suits his/her purposes.
This study aimed to present this group’s experience 
with two last generation prostheses, with coated nitinol 
wires, calling attention to its features, the implantation 
technique, and the results.
METHODS
Study design
This was a single-center, single-arm, retrospective 
review on patients with osASD who underwent per-
cutaneous closure with Lifetech CERA® ASD Occluder 
(Lifetech Scientific Corporation, Shenzhen, China) and 
Cocoon Septal Occluder (Vascular Innovations Co. 
Ltd., Bangtanai, Pakkret, Thailand) prostheses, between 
July 2010 and December 2013. Due to the relatively 
small number of cases, no comparisons were made 
between devices.
Patient selection
In the mentioned period, patients with osASD with 
hemodynamic repercussion and without fixed pulmonary 
hypertension, subjects > 6 years of age and weighing 
at least 15 kg underwent percutaneous occlusion. The 
diagnosis of the defects was established by transthoracic 
echocardiography (TTE) and trans-esophageal echo-
cardiography (TEE), for morphological analysis of the 
defect, identification of rims, and for obtaining the static 
diameter (D), confirming the indication of intervention.
Devices
Lifetech CERA® ASD Occluder
This is a new self-expandable prosthesis, comprising 
a mesh of nitinol (nickel-titanium alloy) composed of 
two disks and a central portion that promote occlu-
sion of the defect, similar to the design of the ASO 
prosthesis. The nitinol wires are coated with a titanium 
nitride compound, which prevents the release of nickel 
into the bloodstream and allow for a quicker and more 
homogeneous endothelial growth with antithrombotic 
properties. Inside the device, a polyester membrane is 
sutured in order to reduce the occurrence of residual 
shunts, accelerating the time to defect occlusion (Figure 1).
This is a very flexible device that conforms well to 
defects and has a satisfactory profile. The central portion 
is 4 mm long and is manufactured in diameters from 6 
mm to 42 mm, in consecutive increments of 2 mm. The 
left disk measures 12 mm more than the center portion 
in devices up to 10 mm, 14 mm more in devices up to 
32 mm, and 16 mm more in other sizes. The right disc 
measures 4 mm less than the left disk in devices up to 
size 32 mm, and 6 mm less in other sizes.
For its loading, the graft is threaded to a metal 
cable and delivered through long 7-14 F sheaths.
Cocoon Septal Occluder
This prosthesis presents a very similar design to 
the previous device. It is also a self-expanding pros-
thesis comprising two discs with a central connector, 
composed of nitinol wires coated with platinum by 
nanofusion, which increases the radiopacity of the 
Figure 1 – Prosthesis CERA®.
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device, facilitating and enhancing its fluoroscopic vi-
sualization and positioning. The platinum coating also 
prevents the release of nickel into the bloodstream, 
preventing nitinol corrosion and increasing the long-
term biocompatibility of the occluder (Figure 2). The 
Coccoon Septal Occluder has satisfactory flexibility, 
with an appropriate conformation to defects.
The length of the central connector is 3 mm in 
8 mm and 10 mm prostheses and 4  mm in the other 
devices. The device has available diameters from 8 
mm to 40 mm in consecutive increments of 2 mm. 
The left disc is 12 mm larger than the central portion 
in prostheses up to 10 mm, and 14 mm larger in the 
other devices. The right disc is 2 mm smaller than the 
left disk in prostheses up to 10 mm, and 4 mm smaller 
in the other devices.
In its interior, the device has a polypropylene mem-
brane sutured in order to minimize the possibility of 
residual shunts, shortening the time to defect occlusion. 
The device is loaded by a thread system and released 
by means of a long 6-12 F sheath.
Procedure
All patients received general anesthesia and orotra-
cheal intubation after a minimum 8-hour fasting. The 
subjects underwent right and left heart catheterization 
via femoral venipuncture and were monitored by TEE 
(three-dimensional, where available). Angiograms were 
not performed.
Heparin was administered in doses of 100 IU/kg for 
children and 5,000 to 10,000 IU in adults, after having 
obtained venous access and with a trans-esophageal 
probe positioned. Cefazolin at doses of 50 mg/kg in 
children or 2 g in adults was administered to all patients 
before and 6 hours after the procedure.
Stretched diameter (SD) measures, with an appro-
priate balloon provided by the retailer company, were 
performed in all cases. The choice of the prosthesis 
was based on SD, with the use of prostheses with sizes 
ranging from the SD up to 4-6 mm larger in cases 
with very thin and defective edges. The prosthesis was 
loaded on the long sheath with a compatible caliber, 
according to the specifications of the manufacturer, and 
released with previously detailed standard techniques.5 
The position of the device was confirmed by TEE; when 
considered satisfactory, the device was detached from 
the delivery system (Figure 3).
Hemostasis was obtained by compression, and all 
patients were extubated in the hemodynamics laboratory 
and transferred to a closed unit until the following day.
Follow-up
TTEs were performed in the day following the 
procedure. 
All patients were instructed to use acetylsalicylic 
acid (3 to 5 mg/kg/day in children and 200 mg/day 
in adults) for six months in association with 75 mg 
of clopidogrel bisulfate, in adults, for three months. 
Adherence to procedures for infective endocarditis 
prophylaxis was recommended for 6 months.
TTEs were performed at one, three, and 12 months, 
and then annually. TEE was performed after six months.
Statistical analysis
Continuous variables were expressed as mean and 
standard deviation and categorical variables as numbers 
and percentages.
RESULTS
As of July 2010, 49 patients underwent percutaneous 
osASD occlusion with use of the prostheses previously 
mentioned; 37 of them were female. The ages ranged 
from 7 to 68 years (32 ± 19 years), and the weights 
from 17 to 90 kg (66 ± 18 kg).
Two patients had suffered ischemic strokes and, at 
that time, were misdiagnosed as having a patent foramen 
ovale in pre-procedure TTEs. A 16-year-old female exhib-
ited transposition of great vessels, having been submitted 
to balloon atrioseptostomy (AS), with subsequent arterial 
switch surgery (Jatene procedure) in the neonatal stage. 
The osASD caused by AS had been left open and needed 
closure. Two months before the osASD occlusion, the 
patient presented some episodes of ventricular tachycardia 
with syncope and received an implantable cardioverter 
defibrillator. Another patient complained of migraine with 
visual changes before implantation. After the procedure, 
the episodes improved, but recurred after the first three 
months. After the implants, migraine was not identified 
in any other patient.Figure 2 – Prosthesis Cocoon. 
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On TEE, an aortic rim was present in 17 cases 
(34.7%) and absent in the others. Atrial septal aneur-
rysm was identified in seven cases (14.3%): five were 
of hypermobile type, swaying to the right/left atrium, 
according to the cardiac cycle (type C), and two bulged 
fixedly towards the right atrium (type A).6
Two patients had associated defects, occluded in 
the same procedure with specific prostheses: a peri-
membranous interventricular communication and a 
patent ductus arteriosus. Seven patients had additional 
orifices with multiple fenestrations in addition to the 
main orifice, and three of them required a second 
prosthesis to completely occlude the orifices.
The static diameter of the major orifices ranged 
from 4 to 32 mm (13 ± 7 mm) and with SDs from 10 
to 36 mm (22 ± 7 mm). The SD obtained with the use 
of the measuring balloon was 33.3% higher than the 
static diameters measured during TEE.
Implant was possible in all cases; 55 devices were 
used in 49 patients with a mean of 1.1 prosthesis by 
patient. CERA® prostheses were used in 45 patients, 
and Cocoon prostheses in four. The diameters of the 
devices implanted in the main orifices ranged from 8 
to 38 mm (24 ± 8 mm), and the most widely used 
diameter was that of 18 mm. Prostheses of 8, 14, and 
16 mm were implanted in three patients who required 
a simultaneous occlusion of the smaller orifices.
During the procedures, it was necessary to replace 
the first prosthesis in three patients. In two cases, the 
initial prosthesis was removed still connected to the 
release cable, and was replaced by another of a larger 
diameter, since the defect suffered dilation during the 
maneuvers of the implant. In the third case, the first 
prosthesis presented a concave shape of the left disk 
during implantation (tuliplike or wine goblet configura-
tion),7 failing to properly adapt to the orifice; it was 
thus withdrawn. SD remeasuring was performed, and 
the prosthesis was replaced by a larger device, which 
was implanted without difficulty.
Immediate (minor) complications were identified in 
four cases. TEE detected filiform thrombi in the exchange 
guide of a patient and in the distal end of the long 
sheath in another patient. All had been heparinized, 
and the procedure did not last longer than usual. An 
additional dose of heparin was applied, and a careful 
removal of affected materials was performed. Then, 
the materials were washed and reintroduced, allow-
ing for the implantation with the traditional technique 
in both cases. No patient had sequelae resulting from 
thrombi, which were not visualized by TEE after re-
moval of the long sheath and guide. Two patients had 
transient arrhythmias: the first showed an exacerbated 
sinus bradycardia for several minutes after completion 
of the procedure during anesthesia reversal, recovering 
without the need for any intervention. Another patient 
had junctional rhythm by manipulating the catheter 
in the right atrium without compromising his cardiac 
output, also with spontaneous resolution.
Mean follow-up was 21 months (1 to 41 months). 
The patient who had junctional rhythm during the 
procedure was hospitalized with atrial fibrillation, with 
rapid ventricular response one month after implantation. 
Currently, this patient is on sinus rhythm and in use 
A B
Figure 3 – Fluoroscopy study showing the prostheses immediately after release: CERA® (A) and Coccoon (B) prostheses. 
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of antiarrhythmic medication. There were no deaths in 
this series. The immediate occlusion rate of 91.9% to 
95.9% at six months was not different from the results 
obtained with the ASO device.5,8 
In the TTE study conducted in the first month, mini-
mal residual shunt was detected in four cases (8.1%), 
three of whom had multiple orifices. One patient, who 
had a very thin septum, required two prostheses. In the 
TTE for control after one month, a significant residual 
shunt was noticed between the two prostheses, which 
were stable and maintained their original positions in 
the interatrial septum. This patient was electively referred 
for surgery, with good results. After the sixth month of 
follow-up, only a trivial leak persisted in one patient; 
another patient, who still had not reached the sixth 
month of follow-up, showed minimal residual shunt.
DISCUSSION
This article focused on the use, handling, and 
results of two new prosthetic coated-nitinol wire 
prostheses about which there is little reference in the 
contemporary literature.3
The first potential advantage of the coated wires is 
to prevent the release of nickel into the bloodstream 
after implantation. In nitinol prosthesis, the release 
of nickel from the device starts immediately after the 
procedure and reaches a maximum after one month, 
and may cause allergic and toxic reactions in sensitive 
patients.9 While this has not proved a problem of great 
magnitude, some cases of occurrence or of worsening 
of migraine in patients undergoing ASO prosthesis 
implantation have been attributed to an allergic reac-
tion to nickel,10 which makes a coating of nitinol wire 
desirable. Another advantage is the increased biocom-
patibility. Coated nitinol wires are more biocompatible 
and less thrombogenic, although the nitinol prostheses 
already have a lower rate of thrombosis compared to 
other metallic devices.11,12
Erosions caused by the prosthesis are rare, but 
potentially fatal. These situations are extremely risky to 
patients, unpredictable, and may be of late occurrence. 
Although its mechanism is still unknown, the erosion 
appears to be related to the abrasion of cardiac tissue 
adjacent to the metallic prosthesis, which can have some 
facilitators, for instance, associated pathologies (Marfan 
syndrome), changes in tissue thickness and composition 
related to age, and variations in tissue resistance and 
in the ability to withstand abrasive forces.13
The oversizing of the device can lead to a contact 
of the edges of the prosthesis with aortic or atrial walls, 
and its movement in relation to the tissue resembles 
a circular saw.14 With respect to the time of appear-
ance, erosions may occur days after implantation or 
even six years later. The mortality rate caused by ero-
sion is 0.004% to 0.015%.15,16 In 2004, the estimated 
incidence of erosion cases in the United States, with 
the use of ASO prosthesis, was 0.1%.12 Other publica-
tions report erosion rates ranging between 0.07% and 
0.11% in the United States, and between 0.04% and 
0.17% in the rest of the world, based on the number 
of ASO sold or implanted.17 Clearly, these numbers are 
only estimates, since many patients do not have their 
implants registered, and many authors do not usually 
report their complications; however, the incidence of 
this complication is fortunately low. Whether due to 
the fewer implants that have been performed, or to the 
smaller number of reports in the literature, or to the 
greater flexibility of the new devices, the fact is that 
no cases of erosion with CERA® and Cocoon prostheses 
have been reported.
No essential differences were observed with respect 
to older prostheses with the same design of those of the 
present study. Both prostheses are easy to handle, of 
simple release, and can be captured and repositioned 
while attached to the delivery system.
The long sheaths of the two devices are more rigid 
and less flexible than desired. In some cases, this causes 
the prosthesis to be positioned perpendicularly to the 
defect, making its implantation difficult. Conversely, 
these devices respond reasonably well to the rotation 
maneuvers that are necessary in such cases. The use 
of the Mullins sheath (Cook Medical Inc., Blooming-
ton, In, United States) or of the new FuStar® sheath 
(Lifetech Scientific Corporation) are excellent alternatives 
for those situations. FuStar® sheaths are long (55, 70, 
80, and 90 mm) and flexible, with deflectable tips of 
3 or 5 cm, which can be curved up to a 160° angle 
by manipulating a cylindrical control in its proximal 
section, providing a better alignment of the prosthesis 
with respect to the orifice (Figure 4).
The malformation “in tulip”, described for CERA® 
prostheses, appears to be exclusive to this device, al-
though the authors managed to reproduce in a bench 
test a similar malformation in a Figulla prosthesis (Oc-
clutech, Prague, Czech Republic). The concave shape of 
the left disk prevents a proper fit of the device to the 
septum and prevents its reintroduction into the sheath. 
This supposedly happens in larger devices, where, to 
Via lateral irrigation
Deflectable tips
Total lenght of the sheath 
Baffle
Figure 4 – FuStar® sheath. Note the baffle cylinder at the proximal end 
of the sheath. The length of its deflectable tip is marked. 
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configure the left disk, it is pushed against the posterior 
wall of the left atrium. Another factor that appears to 
contribute to this malformation is the polyester fabric, 
stuck to the circumference of the device, and which has 
additional sutures in the more distal portion (ceiling) of 
the left disk. If the device takes an abnormal shape, it 
should not be recaptured. Rather, it must be completely 
externalized, noting that it is entirely free within a heart 
chamber (usually the left atrium), and only then trying 
to recapture it. Vigorous attempts to pull the left disc 
inside the sheath will change the nitinol properties, 
making its entry into the long sheath without the aid 
of a loop catheter impossible (Figure 5). It is suggested 
that, in order to avoid this kind of malformation, the 
left disc pin should be held by a forceps and pulled, 
stretching the device while loading it.
CONCLUSIONS
The handling of the prostheses CERA® and Cocoon 
proved to be a simple, safe, and easily reproducible task 
in the hands of experienced surgeons for the closure of 
osASD. Both grafts appeared flexible and with a satisfac-
tory profile. Immediate occlusion rates reproduced those 
in the literature with the Amplatzer® Septal Occluder 
prosthesis, and CERA® and Cocoon prostheses proved 
to be an excellent alternative to traditional prostheses. 
Further studies and long-term follow-up of patients are 
needed in order to determine the real advantages of 
the coating of nitinol wire.
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